Aripiprazole for the treatment of bipolar disorder: a review of current evidence

Bibliography

• Dillenschneider A, Raymond S, McQUade RD, Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, placebo- and haloperidol-controlled study (CN138-162). Eur Arch Psychiatry Clin Neurosci 2007;257(Suppl 2):35
   Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S, A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-8
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20(4):536-46
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
   PubMed Web of Science ®Google Scholar
• Vieta E, Loze JY, T'Joen C, Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Poster presented at WEBP, Strasbourg, France, 13-15 December, 2007
   Google Scholar
• Keck PE Jr, Calabrese JR, McQuade RD, A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-37
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McIntyre RS, Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62(11):841-2
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-40
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Dunn R, In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483(1):45-53
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1(2):141-7
   PubMedGoogle Scholar
• Kane JM, Carson WH, Saha AR, Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
   PubMed Web of Science ®Google Scholar
• Hirose T, Uwahodo Y, Yamada S, Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18(3):375-83
   PubMed Web of Science ®Google Scholar
• Yokoi F, Grunder G, Biziere K, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27(2):248-59
   PubMed Web of Science ®Google Scholar
• Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493(1-3):75-83
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164(9):1411-17
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26(5):649-66
   PubMed Web of Science ®Google Scholar
• Wood MD, Scott C, Clarke K, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006;546(1-3):88-94
   PubMed Web of Science ®Google Scholar
• Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007;8(6):612-22
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40(1):77-97
   PubMed Web of Science ®Google Scholar
• Abilify: US prescribing information. Available from: wwwabilifycom revision 11/2009 [Last accessed 18 October 2010]
   Google Scholar
• Sachs GS, Gaulin BD, Gutierrez-Esteinou R, Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007;68(9):1377-83
   PubMed Web of Science ®Google Scholar
• Suppes T, Eudicone J, McQuade R, Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008;107(1-3):145-54
   PubMed Web of Science ®Google Scholar
• Garcia-Amador M, Pacchiarotti I, Valenti M, Role of aripiprazole in treating mood disorders. Expert Rev Neurother 2006;6(12):1777-83
   PubMedGoogle Scholar
• Zimbroff DL, Marcus RN, Manos G, Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27(2):171-6
   PubMed Web of Science ®Google Scholar
• Boulton DW, Kollia G, Mallikaarjun S, Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008;47(7):475-85
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194(1):40-8
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112(1-3):36-49
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW, Chandler RA, Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006;18(3):169-72
   PubMedGoogle Scholar
• Kemp DE, Dago PL, Straus JL, Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. J Clin Psychopharmacol 2007;27(3):304-5
   PubMed Web of Science ®Google Scholar
• Kemp DE, Gilmer WS, Fleck J, Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):574-7
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Frye MA, Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 2007;101(1-3):275-81
   PubMed Web of Science ®Google Scholar
• Dunn RT, Stan VA, Chriki LS, A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord 2008;110(1-2):70-4
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28(1):13-20
   PubMed Web of Science ®Google Scholar
• Quante A, Zeugmann S, Luborzewski A, Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol 2010;25(2):126-32
   PubMed Web of Science ®Google Scholar
• Muzina DJ, Momah C, Eudicone JM, Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008;62(5):679-87
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16
   PubMedGoogle Scholar
• Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009;31(5):478-83
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Gonda X, Vieta E, Schmidt F. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry 2009;8:27
   PubMedGoogle Scholar
• Tohen M, Sanger TM, McElroy SL, Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
   PubMed Web of Science ®Google Scholar
• Baldessarini R, Henk H, Sklar A, Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008;59(10):1175-83
   PubMed Web of Science ®Google Scholar
• Sachs GS, Gardner-Schuster EE. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl 2007;(434):27-34
   PubMedGoogle Scholar
• McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 2010;19(12):1527-44
   PubMed Web of Science ®Google Scholar
• Andrezina R, Marcus RN, Oren DA, Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006;22(11):2209-19
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328(19):1398-405
   PubMed Web of Science ®Google Scholar
• Ciraulo DA, Nace EP. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 2000;9(4):276-9, discussion 280-274
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10(1):12-21
   PubMed Web of Science ®Google Scholar
• Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005;20(3):179-81
   PubMed Web of Science ®Google Scholar
• Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68(Suppl 6):5-9
   PubMedGoogle Scholar